ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $2,200,000 | -50.6% | 18,743 | -43.4% | 0.00% | -50.0% |
| Q4 2021 | $4,453,000 | +1.3% | 33,100 | +20.0% | 0.00% | 0.0% |
| Q3 2021 | $4,398,000 | +21.3% | 27,591 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $3,626,000 | +41.0% | 27,565 | +38.2% | 0.00% | +100.0% |
| Q1 2021 | $2,571,000 | -19.7% | 19,945 | +3.9% | 0.00% | -50.0% |
| Q4 2020 | $3,200,000 | +105.7% | 19,189 | +90.3% | 0.00% | +100.0% |
| Q3 2020 | $1,556,000 | +13.4% | 10,082 | +8.7% | 0.00% | 0.0% |
| Q2 2020 | $1,372,000 | +73.9% | 9,275 | +32.4% | 0.00% | 0.0% |
| Q1 2020 | $789,000 | +110.4% | 7,005 | +160.0% | 0.00% | – |
| Q4 2019 | $375,000 | -32.4% | 2,694 | -53.2% | 0.00% | – |
| Q3 2019 | $555,000 | +32.5% | 5,758 | +58.4% | 0.00% | – |
| Q2 2019 | $419,000 | +48.1% | 3,636 | +51.3% | 0.00% | – |
| Q1 2019 | $283,000 | +32.9% | 2,403 | -29.4% | 0.00% | – |
| Q4 2018 | $213,000 | – | 3,402 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |